Low-molecular-weight heparin pharmacokinetics: a dual absorption model approach

Abstract

Dalteparin PK profiles after s.c. injection were described reasonably by the novel PPK model based on flip-flop pharmacokinetics and a dual absorption process.

Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response

“…The profiles of the subjects had convex downward curves and straight lines during the absorption phase, as observed in Figure b . Therefore, a one‐compartment model with a transit absorption model, and zero‐order and first‐order parallel absorption with lag time model were tested. In the latter model, the estimated time (1.42 hours) for meloxicam to enter the central compartment according to the zero‐order process was close to the estimated absorption lag time of 1.9 hours with the first‐order rate process.…”

“…Hence, further studies are required to collect data after intravenous administration and at multiple time points during the elimination phase to describe enterohepatic circulation. Moreover, to describe the second peak or delayed absorption in terms of reabsorption after first-pass effect, we tested a zero-order and first-order parallel absorption with lag time model 39 (Figure 1b). In these computations, subjects had convex downward curves or straight lines during the absorption phase, and these interindividual differences were described by the interindividual variability of F. CYP2C9 genotypes and LBMs were statistically significant predictors of CL and Vc, respectively, and similarly decreased clearance in carriers of CYP2C9*2 and/or *3 mutations has been demonstrated for many other drugs.…”